earnings
confidence high
sentiment positive
materiality 0.85
Merck Q3 GAAP EPS $2.32, non-GAAP $2.58; raises full-year non-GAAP EPS guidance to $8.93-8.98
Merck & Co., Inc.
2025-Q3 EPS reported
$6.08
revenue$48,611,000,000
- Total sales $17.3B (+4% YoY, +3% ex-FX); GAAP net income $5.8B, non-GAAP $6.4B.
- KEYTRUDA sales $8.1B (+10%); WINREVAIR $360M (+141%); GARDASIL down 24% to $1.7B.
- Full-year 2025 sales guidance raised to $64.5-65.0B; non-GAAP EPS raised to $8.93-8.98.
- Completed acquisition of Verona Pharma (OHTUVAYRE) in October 2025.
- FDA approved KEYTRUDA QLEX subcutaneous injection for all solid tumor indications.